Amy Hart tried to do everything right.

As soon as she saw that little blue plus sign, she overhauled her diet, prioritizing her unborn baby’s health more than she previously cared for her own.

Believing it was the best decision for her situation, she weaned herself off of Prozac, which was used to tame an anxiety disorder.

And after her baby, Sophie, was born 14 years ago, she didn’t just nod, smile and sign the hospital-issued paper asking new moms to affirm that they watched the SIDS (sudden infant death syndrome) video played on closed-captioned TV, as is required. She watched every minute, which was her tipping point.

Advertise with us

She fixated on the bumper pads she knew lined her baby’s crib at home, which are known risks for suffocation and SIDS. Rather than just making sure to remove them, her thoughts were glued to what might happen if she didn’t, even after the pads were taken away.

Those relentless, intrusive thoughts kept her up most of every night. She repeatedly checked on her baby, who laid in a bassinet a mere foot or two from her and her husband’s bed, just to make sure she was still breathing.

“I could not stop perseverating over it. Could not,” Hart, of Bethel Park, said. “I was up in the middle of the night pumping and crying. I was so tired.”

Hart gathered the courage to restart her Prozac, but relief was still tortuously far away.

“You already feel bad enough. You know you’re out of control. You’re not making sense. Then, you’re taking this medicine, and it’s an awful feeling knowing it’s going to take six weeks to work,” she said. “It’s like a mind game.”

Advertise with us

Stories like Hart’s are all-too common, with postpartum depression affecting about one in seven American women. That’s why there was a collective sigh of relief in early August when the Food and Drug Administration approved Zurzuvae, a first-of-its kind postpartum depression medication, whose effects could be felt by study participants as early as day three.

Zurzuvae is only the second medication approved specifically for postpartum depression. The first is biologically similar to Zurzuvae, with a few major drawbacks: It requires a hospital admission to administer the 60-hour IV infusion, and costs more than $30,000.

Cost and insurance coverage for Zurzuvae aren’t yet known. But for women with PPD, who often feel isolated from typical notions of motherhood and mother-baby bonding, Zurzuvae takes leaps toward accessibility as an oral medication — taken from home — for just 14 days.

For some, this drug could be lifesaving, but that hope comes with some important asterisks.

Suppression and support

Hart’s compulsion to patrol Sophie’s crib each night left her exhausted each day.

Advertise with us
By the time Amy Hart’s daughter, Sophie, was 3 months old, her postpartum mental health required medication and therapy.Tap or slick for larger image.

To cope, she’d retreat to her parents’ house, leave her baby in their care, and sleep for six or seven hours in one of their bedrooms.

That support is part of what helped Hart eventually feel more like herself. But it’s also a privilege denied to many, and might reveal Zurzuvae’s biggest stumbling block to accessibility.

Often, postpartum depression is (successfully) treated with SSRIs (selective serotonin reuptake inhibitors), which allow neurons more access to the feel-good neurotransmitter serotonin by allowing it to pool in the gaps between them.

Zurzuvae attacks postpartum depression with a completely different philosophy.

During pregnancy, there’s a high level of circulating progesterone, and that hormone interacts with GABA, or gamma-aminobutyric acid, receptors in the brain, which can produce a calming effect. In fact, these receptors are the same ones involved in the effects of alcohol and benzodiazepine medications, such as Xanax and Valium.

Advertise with us

The trouble comes when progesterone levels crash after babies are born, which accounts for the unfortunately predictable “baby blues” and, potentially, PPD when moods fail to rebound by about four weeks after birth.

Zurzuvae works on exactly the same receptors progesterone, alcohol and “benzos” do, which is why it’s specific to PPD. Like its mind and mood-altering counterparts, however, Zuzuvae also can cause central nervous system depression — or sedation — leading to a boxed warning issued by the FDA.

The elevated warning sounds like the labels of many other medications: “… Do not drive or engage in other potentially hazardous activities …” For Zurzuvae, that warning lasts for at least 12 hours after taking the nightly dose. But it goes further to say, “ Inform patients that they may not be able to assess their own driving competence, or the degree of driving impairment …”

For many, that’s not a big problem, as written. Few people need to drive in the middle of the night. But medical professionals are interpreting that warning according to how they feel patients might perceive it and their own clinical judgement, given the high-stakes tasks moms do perform in the middle of the night: childcare.

“It’s better to have a secondary caregiver, if you can,” said Allegheny Health Network psychiatrist Emily Smith, who specializes in women’s mental health.

Advertise with us

“The biggest concern is that people are going to be scared to care for a baby, and a lot of infant care takes place overnight,” said Rebecca Brent, clinical psychologist in AHN’s Women’s Behavioral Health Program at West Penn Hospital. “Some might require really significant supports, and a lot of people we see don’t want to not be available to care for the baby, and will avoid medicines that make them sedated. That’s something we see pretty commonly. I do think it will deter some people.”

Amy Hart stopped taking Prozac while pregnant with her daughter Sophie 14 years ago. (Courtesy of Amy Hart)

Dependence and control

Zurzuvae’s interaction with GABA receptors intuitively raises the question of dependence, since both alcohol and benzodiazepines are known to invite abuse for some. But based on the two studies supplied for Zurzuvae’s approval, and basic facts about the drug, that remains to be seen.

“It’s hard to talk about dependence on a medication that you’d probably only be prescribing for a two-week course,” Smith said. “Zurzuvae isn’t a drug we’re thinking about right now for someone having multiple courses of the medication, besides maybe different pregnancies a few years apart.”

But because it does work on GABA receptors, she says, “In someone who has maybe struggled with benzos or alcohol, and has a tendency to be really reinforced by things in that system, it might be something to think about.”

As a result, like benzodiazepines, it will be a federally controlled substance.

Advertise with us

According to co-maker Biogen Inc.’s Aug. 4 news release, knowing the level of control applied to Zurzuvae will take about 90 days. Though it’s only an educated guess, Smith “wouldn’t be surprised” if Zurzuvae is regulated similarly to benzos, which are schedule IV controlled substances, indicating a relatively low potential for abuse.

Another yet-to-be-seen with Zurzuvae is its safety profile for breastfeeding moms, which will receive its own categorization by the FDA.

For Brent, it’s another sobering truth amid the excitement.

“It’s always a positive thing when there’s a new medication, and attention is being given to PPD,” she said. “But I think that it takes a lot of time for a medication to become widespread and accessible to people, so there’s always some caution with a new medication coming out.

“I think it will change things less than the public thinks it will. I don’t think it’s going to be magical.”

Advertise with us

Time, tolerance and tools

Looking back on her postpartum mental health struggle, Hart still feels frustrated at the amount of time it took to feel relief from Prozac: “I have arthritis in my knee. If I had to take ibuprofen for six weeks before it felt better, can you imagine?”

One study submitted to the FDA showed improvement by day three with Zurzuvae, while the other showed significant improvement in depression symptoms by day 15.

But how long does it last?

Biogen Inc. and Sage Therapeutics Inc., creators of Zurzuvae, boast about these effects persisting through 45 days, which was the extent of their studies.

For some patients, that will be enough. But postpartum suicide peaks at six to 12 months after birth, and depressive symptoms can last for months or even years.

Advertise with us

“I would like results that go out longer than 45 days, and I would like to see that data,” Smith said.

If the scientists behind Zurzuvae follow the pattern of others, longer-term safety and efficacy data is likely forthcoming, though maybe not before it’s commercially available by the fourth quarter of this year.

At the very least, it can be used in tandem with other antidepressants, as its studies support. While patients wait for SSRIs to reach peak effect — up to eight weeks — adding Zurzuvae early in treatment could reduce the wait time until relief, benefitting mom, baby and the family as a whole.

“I’m really excited about having another tool in our toolbox because so many people have already tried a lot of the medications that we already have,” Smith said. “Being able to try something new, something that’s specifically targeting PPD, I think it’s going to feel really good for people, and people are going to feel that we’re treating specifically the type of depression that they have, rather than just depression in general.”

It certainly would have for Hart.

Advertise with us

“All you want is to do right by your baby, and you can’t even function,” she said. “It’s an incredible opportunity for new moms who need help to maybe get it in 72 hours.

“I remember Brooke Shields speaking out about PPD, and it was such a big deal. I think this new medication is such a game-changer for that reason. It makes people talk about it.”

If you or someone you know is in crisis related to postpartum depression, consider the National Maternal Mental Health Hotline at 1-833-TLC-MAMA or Resolve Crisis Services at 1-888-796-8226, or call 911.

Abby Mackey is a registered nurse, and can be reached at amackey@post-gazette.com and IG @abbymackeywrites.